- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01267396
Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions
January 10, 2012 updated by: Dr. Reddy's Laboratories Limited
Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fasting Conditions in Healthy Human Adult Subjects.
The objective of this study was to compare and evaluate the single-dose oral bioavailability of the test formulation of Sertraline Hydrochloride 100 mg tablets (Dr.
Reddy's Laboratories Limited) with the reference formulation ZOLOFT® 100 mg Tablet (Pfizer)under fasting conditions in healthy adult human subjects.
Study Overview
Detailed Description
Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover, Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr.
Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fasting Conditions in Healthy Human Adult Subjects.
32 healthy, adult, human male subjects were enrolled in the study and all the subjected completed all the periods.
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ahmedabad
-
Ambawadi, Ahmedabad, India, 380 015
- Veeda Clinical Research (P) Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy human subjects ages 18 and 45 years (including both).
- Subjects weight within the normal range according to normal values for the body mass index (18.5 to 24.9 kg/m2) with minimum of 50 kg weight.
- Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal rane.
- Subjects having normal 12-lead electrocardiogram (ECG)
- Subjects having normal chest X-Ray (P/A view)
- Subjects having negative urine screen for drugs of abuse(including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
- Subjects having negative alcohol breath test
- Subjects willing to adhere to the protocol requirements and to provide written informed consent.
For Female Subjects:
- Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies,diaphragm, intrauterine devise(IUD) or abstinence, or
- Postmenopausal for at least 1 year or
- Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject.
Exclusion Criteria:
- Hypersensitivity to sertraline hydrochloride or related class of drugs.
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological neurological or psychiatric disease or disorder.
- Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
- History or presence of significant alcoholism or drug abuse in the past one year.
- History or presence of significant smoking (more than 10 cigarettes day) or consumption of tobacco products.
- History or presence of significant asthma, urticaria or other allergic reactions.
- History or presence of significant gastric and/or duodenal ulceration.
- History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- History or presence of cancer
- History or presence of significant easy bruising or bleeding
- History or presence of significant recent trauma
- Subjects who have been on an abnormal diet(for whatever reason) during the four weeks preceding the study.
- Difficulty with donating blood
- Difficulty in swallowing solids like tablets or capsules
- Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg
- Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.
- Pulse rate less than 50/minute or more than 100/minute
- Oral temperature less than 95ºF or more than 98.6ºF.
- Respiratory rate less than 12/minute or more than 20/minute
- Use of any prescribed medication during last two weeks or OTC medical products during the last week prior to initiation or study
- Major illness during 3 months before screening
- Participation in a drug research study within past 3 months
- Donation of blood in the past 3 months before screening.
For Female Subjects:
Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study were not allowed to participate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sertraline Hydrochloride tablets 100 mg
Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
|
Sertraline Hydrochloride Tablets 100 mg
Other Names:
|
Active Comparator: Zoloft 100 mg Tablets
Zoloft 100 mg Tablets of Pfizer
|
Sertraline Hydrochloride Tablets 100 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence based on Cmax and AUC parameters
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Damesh Domadia, MBBS, M.D, Veeda Clinical Research (P) Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
September 1, 2006
Study Completion (Actual)
October 1, 2006
Study Registration Dates
First Submitted
December 27, 2010
First Submitted That Met QC Criteria
December 27, 2010
First Posted (Estimate)
December 28, 2010
Study Record Updates
Last Update Posted (Estimate)
January 11, 2012
Last Update Submitted That Met QC Criteria
January 10, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-VIN-103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Sertraline
-
Beijing HuiLongGuan HospitalCompleted
-
Maastricht University Medical CenterPfizerCompletedDepression | Chest Pain | Panic AttacksNetherlands
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
University of Sao PauloCompletedObsessive-Compulsive DisorderBrazil
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI)CompletedDepression | Myocardial Infarction | Heart Diseases | Cardiovascular Diseases | Angina, UnstableUnited States
-
TakedaCompletedCrohn's Disease | Ulcerative ColitisBelgium, United States, Korea, Republic of, Malaysia, Canada, Israel, Australia, Hungary, Czechia, Germany
-
University of PittsburghCompleted
-
Su RuiUnknown
-
Rhode Island HospitalStanford University; University of Cincinnati; American Epilepsy Society; Epilepsy...CompletedDepression | Stress Disorders, Post-Traumatic | Dissociative Disorders | Conversion Disorder | Convulsion, Non-EpilepticUnited States
-
TakedaCompleted